# Will Natera, Inc. report Above 4.25 million tests processed in fiscal 2026

> Above 4.2 million leads at 72%, runner-up 47% across 4 winner-take-all outcomes — refreshed 28 min ago.

URL: https://simplefunctions.dev/odds/ntraa
Updated: 2026-08-27T11:21:44.841Z
Category: general
Status: active
Closes: 2027-05-27

## Headline

- Leader: Above 4.2 million at 72%
- Runner-up: Above 4.25 million at 47%
- Outcomes: 4 (winner-take-all)
- Venue: Kalshi (4 contracts)
- 24h volume: $0

## Bound contracts (4)

| Outcome | Price | 24h | Volume | Venue | Slug |
|---|---|---|---|---|---|
| Above 4.2 million | 72¢ | −20pp | $0 | kalshi | /markets/will-natera-inc-report-above-42-million-tests-proc-kalshi-kxntraa-27febtests-4200000 |
| Above 4.25 million | 47¢ | −13pp | $0 | kalshi | /markets/will-natera-inc-report-above-425-million-tests-pro-kalshi-kxntraa-27febtests-4250000 |
| Above 4.3 million | 22¢ | ±0 | $0 | kalshi | /markets/will-natera-inc-report-above-43-million-tests-proc-kalshi-kxntraa-27febtests-4300000 |
| Above 4.35 million | 6¢ | ±0 | $0 | kalshi | /markets/will-natera-inc-report-above-435-million-tests-pro-kalshi-kxntraa-27febtests-4350000 |

## 30-day trajectory

| Day | Above 4.2 million | Above 4.25 million | Above 4.3 million |
|---|---|---|---|
| 2026-08-13 | 34 | 22 | 8 |
| 2026-08-20 | 53 | 38 | 17 |
| 2026-08-26 | 52 | 34 | 22 |

_12 days of price history captured. Each row is the daily mean of intraday 5-min captures._

## What moved the line

- 2026-08-26 · Above 4.2 million −20pp 72→52¢ · kalshi
- 2026-08-21 · Above 4.2 million +19pp 53→72¢ · kalshi
- 2026-08-26 · Above 4.25 million −13pp 47→34¢ · kalshi
- 2026-08-20 · Above 4.25 million +10pp 28→38¢ · kalshi
- 2026-08-21 · Above 4.25 million +9pp 38→47¢ · kalshi

## Analysis

This contract reflects market expectations that Natera will process at least 4.25 million tests during fiscal year 2026. At 46%, traders assess this outcome as less likely than the 4.2 million threshold but still plausible. The probability reflects uncertainty around Natera's test volume growth trajectory, which depends on adoption rates across their product lines—including prenatal, cancer, and transplant testing—and their ability to expand laboratory capacity and customer relationships. Key catalysts include quarterly earnings reports throughout 2026 and management guidance on annual test volumes. The pricing gradient across thresholds (71% for 4.2M, 46% for 4.25M, 21% for 4.3M) suggests markets see modest growth from current run rates as the base case, with higher volumes viewed as requiring stronger-than-expected execution or market conditions. Resolution will occur when Natera reports full fiscal 2026 results, typically in early 2027.

### Key factors

- Natera's reported test volumes in fiscal 2025 and Q1-Q2 2026 results, which establish the baseline for assessing trajectory toward 4.25 million
- Quarterly earnings guidance and management commentary on test volume trends across prenatal, oncology, and organ transplant segments
- Competitive dynamics and market share shifts in genetic testing, particularly in prenatal screening where Natera faces established competitors
- Laboratory capacity constraints or expansions announced by Natera that would affect processing volume ceiling
- Healthcare reimbursement changes or policy shifts affecting test demand or Natera's addressable market during 2026

## Methodology

Headline is the **leader's price**, not an arithmetic mean — averaging disjoint winner-take-all outcomes is meaningless. Per-outcome prices come from the venue's last-traded mid; cross-venue values are simple means across contracts on each venue.

## How to use this data

- HTML: https://simplefunctions.dev/odds/ntraa
- JSON: https://simplefunctions.dev/api/public/odds?slug=ntraa

## License

CC-BY-4.0. Attribute "SimpleFunctions" with a link to https://simplefunctions.dev. See https://simplefunctions.dev/legal for terms.